From: COVID-19 versus applied infection control policies in a Major Transplant Center in Iran
Variable | COVID-19 PCR Positive (%) n = 21 | COVID-19 PCR negative patients but highly suspicious (%) n = 56 |
---|---|---|
Age group | ||
  < 40 | 3 (14.3) | 7 (10.7) |
 40–60 | 10 (47.6) | 17 (28.6) |
  > 60 | 8 (38.1) | 32 (57.1) |
Gender | ||
 Male | 12 (57.1) | 38 (67.9) |
 Female | 9 (42.9) | 18 (32.1) |
Residence (Fars province) | ||
 Shiraz (capital of Fars) | 9 (42.9) | 34 (60.7) |
 Other Cities | 12 (57.1) | 22 (39.2) |
Comorbid diseases | ||
 Diabetes mellitus | 6 (28.5) | 17 (30.4) |
 Cirrhosis | 5 (23.8) | 14 (25) |
 Hypertension | 4 (19.0) | 18 (32.1) |
 Ischemic heart disease | 2 (9.5) | 1 (1.8) |
 Encephalopathy | 1 (9.5) | 5 (8.9) |
 Asthma | 1 (4.8) | 0 (0) |
 Ascites | 1 (4.8) | 3 (5.4) |
 End-stage renal disease | 1 (4.8) | 7 (12.5) |
 Chronic obstructive pulmonary disease | 0 (0) | 4 (7.1) |
 Deep venous thrombosis | 0 (0) | 1 (1.8) |
Symptoms | ||
 Fever | 11 (52.4) | 17 (30.4) |
 Cough | 6 (28.6) | 13 (23.2) |
 Dyspnea | 6 (28.6) | 20 (35.7) |
 Vomiting | 5 (23.8) | 8 (14.3) |
 Diarrhea | 3 (14.3) | 6 (10.7) |
 Headache | 3 (14.3) | 2 (3.6) |
 Pharyngitis | 0 (0) | 0 (0) |
 Rhinorrhea | 0 (0) | 0 (0) |
 Chest pain | 0 (0) | 0 (0) |
 Malaise | 0 (0) | 0 (0) |
Transplantation Status | ||
 Liver transplant | 5 (23.8) | 4 (7.1) |
 Kidney transplant | 3 (14.3) | 4 (7.1) |
 Candidate for transplant | 8 (38.1) | 15 (26.8) |
Time after transplant (months) | ||
 1–3 | 0 (0) | 2 (25) |
 3–6 | 2 (22.2) | 2 (25) |
 6–12 | 3 (33.3) | 1 (12.5) |
  > 12 | 4 (44.4) | 3 (37.5) |